Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued 2 new positive opinions for products related to the treatment of patients with diabetes.
The CHMP recommended granting market authorization for Novo-Nordisk's Xultophy, a fixed-dose (100 units/mL + 3.6 mg/mL) combination of the basal insulin analog degludec and the glucagon-like peptide-1 receptor agonist liraglutide.
The combination product lowers glucose in patients with type 2 diabetes via 2 mechanisms: insulin degludec binds specifically to the human insulin receptor, providing the same pharmacological effect as human insulin, and liraglutide enhances glucose-dependent insulin secretion and diminishes glucagon release.
http://www.medscape.com/viewarticle/828930
(free registration required)
The CHMP recommended granting market authorization for Novo-Nordisk's Xultophy, a fixed-dose (100 units/mL + 3.6 mg/mL) combination of the basal insulin analog degludec and the glucagon-like peptide-1 receptor agonist liraglutide.
The combination product lowers glucose in patients with type 2 diabetes via 2 mechanisms: insulin degludec binds specifically to the human insulin receptor, providing the same pharmacological effect as human insulin, and liraglutide enhances glucose-dependent insulin secretion and diminishes glucagon release.
http://www.medscape.com/viewarticle/828930
(free registration required)